Last reviewed · How we verify
GSK573719/GW642444 Inhalation Powder
GSK573719/GW642444 Inhalation Powder is a LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
GSK573719/GW642444 is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and reduces mucus secretion to improve airflow in chronic obstructive pulmonary disease.
GSK573719/GW642444 is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and reduces mucus secretion to improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | GSK573719/GW642444 Inhalation Powder |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) |
| Target | M3 muscarinic receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
GSK573719 (umeclidinium) blocks muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. GW642444 (vilanterol) activates beta-2 adrenergic receptors, causing bronchodilation. Together, these complementary mechanisms provide dual bronchodilation for sustained airway opening and improved lung function in COPD patients.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nasopharyngitis
Key clinical trials
- A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD (PHASE3)
- A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (PHASE3)
- A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD (PHASE3)
- A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects (PHASE1)
- QTc Study GSK573719+GW642444 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK573719/GW642444 Inhalation Powder CI brief — competitive landscape report
- GSK573719/GW642444 Inhalation Powder updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK573719/GW642444 Inhalation Powder
What is GSK573719/GW642444 Inhalation Powder?
How does GSK573719/GW642444 Inhalation Powder work?
What is GSK573719/GW642444 Inhalation Powder used for?
Who makes GSK573719/GW642444 Inhalation Powder?
What drug class is GSK573719/GW642444 Inhalation Powder in?
What development phase is GSK573719/GW642444 Inhalation Powder in?
What are the side effects of GSK573719/GW642444 Inhalation Powder?
What does GSK573719/GW642444 Inhalation Powder target?
Related
- Drug class: All LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) drugs
- Target: All drugs targeting M3 muscarinic receptor; beta-2 adrenergic receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Compare: GSK573719/GW642444 Inhalation Powder vs similar drugs
- Pricing: GSK573719/GW642444 Inhalation Powder cost, discount & access